查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495994

全球心臟去颤器市场：2024-2029 年预测

Global Defibrillators Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计心臟去颤器市场在预测期内将以 5.32% 的复合年增长率成长，从 2022 年的 145.79 亿美元增至 2029 年的 209.58 亿美元。

心臟去颤器是一种向心臟提供电击以恢復心率的医疗设备。该装置可防止或纠正可能导致心臟麻痹的不均匀心率。随着人口老化，心臟病和搭桥手术的盛行率持续增加。例如，根据世界卫生组织（WHO）的数据，2019年，有1,790万人因心血管疾病死亡，占全球死亡人数的32%。

此外，根据美国疾病管制与预防中心的数据，2020 年美国有 697,000 人死于心臟病。此外，根据欧盟统计局的数据，2020 年德国进行了 38,900 例心臟绕道手术，是欧盟成员国手术数量的两倍多。鑑于心臟病死亡人数和搭桥手术数量不断增加，未来对心臟去颤器的需求和使用预计也会增加，从而导致心臟去颤器。

全球心臟去颤器市场按类型分为自动体外心臟去颤器（AED）、植入式心臟整流去颤器（ICD）和可穿戴式心臟去颤器（WCD）。预计自动体外心臟去颤器在预测期内将出现相对较高的成长率。自动体外心臟去颤器在治疗心臟麻痹方面用途极为广泛，因为它们可以与心肺復苏术结合以增加復苏的机会。

该设备是便携式的，可以自动分析心臟麻痹患者的心率。由于自动体外心臟去颤器的高性能以及心臟衰竭患者数量的增加，预计需求将会增加，这似乎将促进同一细分市场的成长以及心臟去颤器市场在预测期内的成长。

市场驱动因素：

  • 心臟麻痹率的上升预计将推动心臟去颤器市场的发展。

由于院外心臟麻痹的发生率不断增加以及体外心臟去颤器提供的舒适性，心臟去颤器市场预计将成长。已开发国家的政府法规鼓励在公共场所安装体外心臟去颤器，像 LifeVest 这样的可穿戴式心臟去颤器现已在某些地区上市。

体外心臟去颤器预计将变得普及，因为它们比植入式心臟去颤器更安全。心臟麻痹是一种危及生命的疾病，通常需要即时进行去心房颤动。心臟麻痹是一种时间敏感事件，需要快速、时间敏感的干预，因此需要易于使用且精心放置的心臟去颤器。公共去心房颤动计划旨在在公共场所提供 AED 并增加早期去心房颤动的机会。

在医疗机构中，早期去心房颤动被优先视为心臟麻痹病例管理中生存链的一部分。基本生命支持和心肺復苏术培训等培训和意识提升工作正在不断增加，人们对去心房颤动在心臟麻痹期间挽救生命的重要性的认识也在不断增强。

  • 政府的措施和投资正在导致心臟去颤器市场的需求激增。

心臟去颤器在心臟麻痹的情况下提供维持个人心率所需的紧急援助，这种情况可能发生在任何地方。有鑑于心臟病日益严重的威胁，政府当局正在实施各种倡议、计划和投资来解决这些与健康相关的问题。例如，2022年5月，德里政府在公车站、火车站、市场等公共场所安装了自动体外心臟去颤器。此外，2021 年 3 月，兰金政府宣布将投资 70 万美元在新斯科细亚省的所有公立学校安装自动体外心臟心臟去颤器。

此外，威尔斯政府于 2022 年 2 月宣布计划增加公共机构、社区团体和运动场的心臟去颤器供应，以提高院外心臟麻痹患者的生存率，并宣布投资 6.768 亿美元。这种有利的投资和改善公共场所使用心臟去颤器的计划将导致该设备的需求和使用激增，从而在预测期内推动全球市场的成长。

主要进展

  • 2023 年 8 月 - 皇家飞利浦展示了心臟超音波和人工智慧在心臟护理中的集成，以提高临床可靠性并提高效率。可携式设备飞利浦超音波紧凑系统 5500 CV 包括人工智慧驱动的自动化工具，用于应变量化并评估心臟的左心室功能。飞利浦心臟超音波技术每年支援超过 2.4 亿名患者的诊断和治疗。该公司在其心臟超音波产品组合中提供人工智慧驱动的技术，包括完整的心臟 3D 量化和建模、自动 2D 多普勒和长度测量、可重复的 2D 应变量化以及二尖瓣动态分析。
  • 2023 年 5 月 -远端患者监护和心臟资料管理解决方案领域的领导者 Implicity 公布了与法国政府健康资料中心合作进行的一项研究结果。这项研究根据心臟植入电子设备 (CIED) 患者的真实资料，比较了不同远端监测方法之间的 1 年死亡率、每位患者的住院情况以及住院时间。结果表明，根据所使用的远端监测方法，死亡率存在很大差异。
  • 2023 年 2 月 -Medtronic推出 Aurora EV-ICD(TM) MRI SureScan(TM) 和 Epsila EV(TM) MRI SureScan(TM)去心房颤动。 Aurora EV-ICD 系统提供传统 ICD 的救生优势，同时透过在心臟和静脉外部放置细线来避免风险。该系统正在美国接受临床实验，将为植入 Aurora EV-ICD 的患者提供去心房颤动、抗心搏过速起搏和备用心律调节治疗。 Aurora EV-ICD 将植入您的左腋下，Epsila EV 导线将植入您的胸骨下方。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球心臟去颤器市场：按类型

  • 介绍
  • 自动体外电击器(AED)
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 植入式心臟整流去颤器(ICD)
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 心臟去颤器(WCD)
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章心臟去颤器全球市场：依最终用户分类

  • 介绍
  • 医院/诊所
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 门诊手术中心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章心臟去颤器全球市场：按地区

  • 介绍
  • 北美洲
    • 按类型
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 按类型
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 按类型
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 按类型
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 按类型
    • 按最终用户
    • 按国家/地区

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第九章 公司简介

  • Boston Scientific Corporation
  • Medtronic
  • ZOLL Medical Corporation
  • AbbottAbott
  • Defibtech LLC
  • Koninklijke Philips NV
  • Nihon Kohden Corporation
  • Schiller AG
  • Stryker Corporation
  • Bexen Cardio
简介目录
Product Code: KSI061611897

The global defibrillators market is expected to grow at a CAGR of 5.32% over the forecast period to reach US$20.958 billion by 2029 from US$14.579 billion in 2022.

The defibrillator is a medical equipment that is used to send an electrical shock to the heart for the restoration of the heartbeat. The equipment prevents or corrects uneven heartbeat, which could lead to sudden cardiac arrest. The prevalence of heart disease and bypass surgeries are showing a constant rise coupled with the growing old age population. For instance, according to the World Health Organization, in 2019, the number of deaths recorded due to cardiovascular disease stood at 17.9 million, which represented 32% of all global deaths.

Furthermore, according to the Centers for Disease Control and Prevention, in 2020, in the United States, the number of deaths recorded due to heart disease stood at 697,000. Moreover, according to Eurostat, in 2020, 38,900 heart bypass surgeries were conducted in Germany, which was more than double the number of surgeries conducted in any of the EU's member states. Owing to such a high death count due to heart diseases and an increase in bypass surgeries, the demand and usage of defibrillators in such instances are also projected to increase in the future, thereby boosting the global defibrillator market growth during the forecast period.

The global defibrillator market is segmented based on its type into automated external defibrillators (AED), implantable cardioverter defibrillators (ICD), and wearable cardio defibrillators (WCD). The automated external defibrillator is expected to grow at a relatively higher rate during the forecast period. They are highly applicable during the treatment of sudden cardiac arrest, as the combination of the equipment with CPR improves the resuscitation chances.

The equipment is portable and can automatically analyze the heart rate of an individual experiencing cardiac arrest. Owing to its high-performance features coupled with growing cases of heart failure, the demand for automated external defibrillators is projected to increase, thereby improving the segment growth as well as the global defibrillators market growth during the forecast period.

Market Drivers:

  • Rising prevalence of sudden cardiac arrest is expected to drive the defibrillator market.

The defibrillator market is expected to grow due to the increasing prevalence of out-of-hospital cardiac arrests and the comfort offered by external defibrillators. Government regulations in developed nations are driving the installation of external defibrillators in public places, with wearable defibrillators like LifeVest being launched in certain regions.

The safety of external defibrillators compared to implantable ones is projected to increase adoption. Sudden cardiac arrest is a life-threatening condition that requires immediate intervention, often involving defibrillation. The time-critical nature of sudden cardiac arrest necessitates prompt and time-critical intervention, leading to the demand for accessible and strategically placed defibrillators. Public access defibrillation programs aim to make AEDs available in public spaces, increasing the chances of early defibrillation.

Healthcare settings are prioritizing early defibrillation as part of the chain of survival in managing sudden cardiac arrest cases. Increased training and awareness initiatives, such as basic life support and cardiopulmonary resuscitation training, contribute to increased awareness about the importance of defibrillation in saving lives during sudden cardiac arrest events.

  • The favorable government initiatives and investments are creating a surge in the market for defibrillators demand.

Defibrillators provide the urgent assistance required to maintain the heartbeat of an individual during a sudden cardiac arrest situation, which can occur anywhere. Realizing the growing threat of heart disease, various initiatives, schemes, and investments have been implemented by the governing authorities to tackle such health-related issues. For instance, in May 2022, the Delhi government announced its plans to install automated external defibrillators in public places such as bus stops, railway stations, and marketplaces to provide quick medical assistance to people who suffer cardiac arrest in public places. Additionally, in March 2021, the Rankin government announced investments of US$700,000 to install automated external defibrillators in all public schools in Nova Scotia.

Furthermore, in February 2022, the Welsh government announced investments of US$676.8 million to increase the availability of defibrillators in public organizations, community groups, and sports grounds to improve the survival rate of people who suffer sudden cardiac arrest outside the hospitals. Such favorable investments and plans to increase access to defibrillators in public places will create a surge in the demand and usage of the equipment, thereby boosting their market growth at a global level during the forecast period.

Key Developments:

  • August 2023- Royal Philips as showcased its integration of AI in cardiac ultrasound and cardiac care to improve clinical confidence and increase efficiency. The Philips Ultrasound Compact System 5500 CV, a portable device, includes an AI-powered automation tool for strain quantification, assessing the heart's left ventricle function. Philips' cardiac ultrasound technology supports the diagnosis and treatment of over 240 million patients annually. The company is a leader in integrating AI-powered technology across its cardiac ultrasound portfolio, including full 3D quantification and modeling of the heart, automated 2D Doppler and length measurements, reproducible 2D strain quantification, and dynamic analysis of the mitral valve.
  • May 2023- Implicity, a leader in remote patient monitoring and cardiac data management solutions, revealed the results of a study conducted in collaboration with the French government's Health Data Hub. The study compared mortality rates, hospitalizations per patient, and hospital stays in a year based on real-world data from patients with cardiac implantable electronic devices (CIEDs) to various remote monitoring methods. Results showed significant disparities in mortality rates based on the method of remote monitoring used. Implicity's universal, alert-based remote monitoring platform was associated with better performance compared to historical manufacturers' solutions.
  • February 2023- Medtronic received CE Mark for the Aurora EV-ICD(TM) MRI SureScan(TM) and Epsila EV(TM) MRI SureScan(TM) defibrillation lead, designed to treat fast heart rhythms that can lead to sudden cardiac arrest. The Aurora EV-ICD system offers the life-saving benefits of traditional ICDs while avoiding risks due to its thin wire placement outside the heart and veins. The system is investigational in the United States and offers defibrillation, anti-tachycardia pacing, and backup pacing therapies for patients implanted with the Aurora EV-ICD. The Aurora EV-ICD is implanted below the left armpit, and the Epsila EV lead is placed under the breastbone.

Segmentation:

By Type

  • Automated External Defibrillator (AED)
  • Implantable Cardioverter-Defibrillator (ICD)
  • Wearable Cardio Defibrillator (WCD)

By End-User

  • Hospitals & Clinics
  • Ambulatory Surgical Center
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • United Arab Emirates
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL DEFIBRILLATORS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Automated External Defibrillator (AED)
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Implantable Cardioverter-Defibrillator (ICD)
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Wearable Cardio Defibrillator (WCD)
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. GLOBAL DEFIBRILLATORS MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Hospitals & Clinics
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Ambulatory Surgical Center
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Others
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness

7. GLOBAL DEFIBRILLATORS MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Type
    • 7.2.2. By End-User
    • 7.2.3. By Country
      • 7.2.3.1. USA
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Type
    • 7.3.2. By End-User
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Type
    • 7.4.2. By End-User
    • 7.4.3. By Country
      • 7.4.3.1. Germany
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. France
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. United Kingdom
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Italy
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Spain
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
      • 7.4.3.6. Others
        • 7.4.3.6.1. Market Opportunities and Trends
        • 7.4.3.6.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Type
    • 7.5.2. By End-User
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. Israel
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. United Arab Emirates
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
      • 7.5.3.4. Others
        • 7.5.3.4.1. Market Opportunities and Trends
        • 7.5.3.4.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Type
    • 7.6.2. By End-User
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. Japan
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. South Korea
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. India
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. Australia
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Indonesia
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Thailand
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Taiwan
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects
      • 7.6.3.9. Others
        • 7.6.3.9.1. Market Opportunities and Trends
        • 7.6.3.9.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Boston Scientific Corporation
  • 9.2. Medtronic
  • 9.3. ZOLL Medical Corporation
  • 9.4. AbbottAbott
  • 9.5. Defibtech LLC
  • 9.6. Koninklijke Philips N.V
  • 9.7. Nihon Kohden Corporation
  • 9.8. Schiller AG
  • 9.9. Stryker Corporation
  • 9.10. Bexen Cardio